PE103799A1 - Procedimiento de purificacion de mesilato de alatrofloxacino - Google Patents

Procedimiento de purificacion de mesilato de alatrofloxacino

Info

Publication number
PE103799A1
PE103799A1 PE1998000667A PE00066798A PE103799A1 PE 103799 A1 PE103799 A1 PE 103799A1 PE 1998000667 A PE1998000667 A PE 1998000667A PE 00066798 A PE00066798 A PE 00066798A PE 103799 A1 PE103799 A1 PE 103799A1
Authority
PE
Peru
Prior art keywords
alatrofloxacino
mesylate
purification procedure
compound
formula
Prior art date
Application number
PE1998000667A
Other languages
English (en)
Inventor
Robert Mark Guinn
John Francis Lambert
Stanley Walter Walinsky
Subramanian Sam Guhan
Original Assignee
Pfizer Prod Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Prod Inc filed Critical Pfizer Prod Inc
Publication of PE103799A1 publication Critical patent/PE103799A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06008—Dipeptides with the first amino acid being neutral
    • C07K5/06017—Dipeptides with the first amino acid being neutral and aliphatic
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06191—Dipeptides containing heteroatoms different from O, S, or N
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Abstract

SE REFIERE A UN PROCEDIMIENTO PARA PURIFICAR UN COMPUESTO DE FORMULA (I), QUE COMPRENDE: TRATAR UN PRODUCTO DE REACCION IMPURO E IMPUREZAS POCO POLARES DE FORMULA (II), CON UNA RESINA HIDROFOBA TAL COMO UNA RESINA DE POLIESTIRENO RETICULADO; DICHAS IMPUREZAS POCO POLARES SE CARACTERIZAN POR SU TIEMPO DE RETENCION EN CROMATOGRAFIA LIQUIDA DE ALTA PERFORMANCE (HPLC). DESPUES DEL TRATAMIENTO LAS IMPUREZAS SOLO REPRESENTARIAN 60 ppm. LA COMPOSICION COMPRENDE DE 10 mg A 700 mg DEL COMPUESTO (I), EL QUE SE PUEDE USAR COMO UN ANTIBACTERIANO
PE1998000667A 1997-08-01 1998-07-24 Procedimiento de purificacion de mesilato de alatrofloxacino PE103799A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US5424697P 1997-08-01 1997-08-01

Publications (1)

Publication Number Publication Date
PE103799A1 true PE103799A1 (es) 1999-10-25

Family

ID=21989735

Family Applications (1)

Application Number Title Priority Date Filing Date
PE1998000667A PE103799A1 (es) 1997-08-01 1998-07-24 Procedimiento de purificacion de mesilato de alatrofloxacino

Country Status (40)

Country Link
US (1) US6194429B1 (es)
EP (1) EP1000086B1 (es)
JP (1) JP3463928B2 (es)
KR (1) KR20010022495A (es)
CN (1) CN1265671A (es)
AP (1) AP1031A (es)
AR (1) AR015417A1 (es)
AT (1) ATE259827T1 (es)
AU (1) AU734863B2 (es)
BG (1) BG104105A (es)
BR (1) BR9811580A (es)
CA (1) CA2296466C (es)
CO (1) CO4970688A1 (es)
DE (1) DE69821767T2 (es)
DK (1) DK1000086T3 (es)
DZ (1) DZ2576A1 (es)
EA (1) EA002120B1 (es)
ES (1) ES2214716T3 (es)
GT (1) GT199800112A (es)
HN (1) HN1998000106A (es)
HR (1) HRP980417B1 (es)
HU (1) HUP0004793A3 (es)
ID (1) ID24374A (es)
IL (1) IL134156A0 (es)
IS (1) IS5339A (es)
MA (1) MA24626A1 (es)
NO (1) NO20000485L (es)
NZ (1) NZ502249A (es)
OA (1) OA11281A (es)
PA (1) PA8456701A1 (es)
PE (1) PE103799A1 (es)
PL (1) PL338477A1 (es)
PT (1) PT1000086E (es)
SK (1) SK1012000A3 (es)
TN (1) TNSN98146A1 (es)
TW (1) TW538043B (es)
UY (1) UY25113A1 (es)
WO (1) WO1999006430A1 (es)
YU (1) YU2500A (es)
ZA (1) ZA986874B (es)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE285821T1 (de) * 1999-10-08 2005-01-15 Affinium Pharm Inc Fab i inhibitoren
EP1121933A1 (en) * 2000-02-02 2001-08-08 Pfizer Products Inc. Premixed alatrofloxacin injectable compositions
WO2003088897A2 (en) 2001-04-06 2003-10-30 Affinium Pharmaceuticals, Inc. Fab i inhibitors
EP1575951B1 (en) 2002-12-06 2014-06-25 Debiopharm International SA Heterocyclic compounds, methods of making them and their use in therapy
EP1608377B1 (en) 2003-03-17 2008-10-01 Affinium Pharmaceuticals, Inc. Pharmaceutical compositions comprising inhibitors of fab i and further antibiotics
CA2467321A1 (en) * 2004-05-14 2005-11-14 Paul J. Santerre Polymeric coupling agents and pharmaceutically-active polymers made therefrom
EP1828167B1 (en) * 2004-06-04 2014-08-06 Debiopharm International SA Acrylamide derivatives as antibiotic agents
CA2632476A1 (en) * 2005-12-05 2007-06-14 Affinium Pharmaceuticals, Inc. Heterocyclylacrylamide compounds as fabi inhibitors and antibacterial agents
US8318720B2 (en) 2006-07-20 2012-11-27 Affinium Pharmaceuticals, Inc. Acrylamide derivatives as Fab I inhibitors
WO2008098374A1 (en) 2007-02-16 2008-08-21 Affinium Pharmaceuticals, Inc. Salts, prodrugs and polymorphs of fab i inhibitors
HUE043836T2 (hu) 2012-06-19 2019-09-30 Debiopharm Int Sa (E)-N-metil-N-((3-metilbenzofuran-2-il)metil)-3-(7-oxo-5,6,7,8-tetrahidro-1,8-naftiridin-3-il)akrilamid prodrug származékai
EP3134103B1 (en) * 2014-04-25 2020-01-15 Naurex Inc. Stable compositions of neuroactive peptides
MY189221A (en) 2016-02-26 2022-01-31 Debiopharm Int Sa Medicament for treatment of diabetic foot infections
JP2021512852A (ja) 2018-02-02 2021-05-20 リップル セラピューティクス コーポレーション ステロイド二量体を含むガラス製剤およびその使用
WO2021220061A2 (en) 2020-05-01 2021-11-04 Ripple Therapeutics Corporation Heterodimer compositions and methods for the treatment of ocular disorders

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3713672A1 (de) 1987-04-24 1988-11-17 Bayer Ag Verfahren zur herstellung von parenteral verabreichbaren chinoloncarbonsaeuren
US5164402A (en) 1989-08-16 1992-11-17 Pfizer Inc Azabicyclo quinolone and naphthyridinone carboxylic acids
US5256791A (en) 1992-03-02 1993-10-26 Pfizer Inc. Preparation of intermediates in the synthesis of quinoline antibiotics
PL179996B1 (en) 1994-01-18 2000-11-30 Pfizer Method of and intermediate products for obtaining salts of naphtyridinocarboxylic acids
TW420610B (en) 1994-04-07 2001-02-01 Pfizer A pharmaceutical composition for treating a H. pylori infection or gastric or duodenal ulcers
US5475116A (en) 1994-04-29 1995-12-12 Pfizer Inc. Aza bicyclo[3,1,0]hexane intermediates useful in the synthesis of quinolones
SK280535B6 (sk) 1995-06-06 2000-03-13 Pfizer Inc. Kryštalická forma bezvodej soli kyseliny 7-([1a,5a
CA2224616C (en) 1995-06-15 2000-05-02 Michael J. Castaldi Process for preparing derivatives of azabicyclo naphthyridine carboxylic acid comprising a dipeptide
RU2151152C1 (ru) 1995-08-29 2000-06-20 Пфайзер Инк. Полиморфы 6-n-(l-ala-l-ala)-тровафлоксацина
HUP9900170A3 (en) 1995-08-29 1999-11-29 Pfizer Zwitterionic forms of trovafloxacin, process for producing them and medicaments containing the same
GB9524466D0 (en) 1995-11-30 1996-01-31 Pfizer Ltd Process
JPH1087617A (ja) 1996-07-09 1998-04-07 Pfizer Inc キノリン系抗生物質の合成に有用な中間体の製法

Also Published As

Publication number Publication date
YU2500A (sh) 2002-09-19
CA2296466C (en) 2003-04-15
PT1000086E (pt) 2004-05-31
GT199800112A (es) 2000-01-15
AP1031A (en) 2001-12-21
ES2214716T3 (es) 2004-09-16
HN1998000106A (es) 1999-01-08
AP9801310A0 (en) 1998-09-30
IL134156A0 (en) 2001-04-30
NO20000485D0 (no) 2000-01-31
DE69821767D1 (de) 2004-03-25
AU8236898A (en) 1999-02-22
WO1999006430A1 (en) 1999-02-11
EA002120B1 (ru) 2001-12-24
BR9811580A (pt) 2000-08-22
DE69821767T2 (de) 2005-01-13
JP2001512133A (ja) 2001-08-21
KR20010022495A (ko) 2001-03-15
AU734863B2 (en) 2001-06-21
BG104105A (bg) 2000-08-31
NO20000485L (no) 2000-03-27
CN1265671A (zh) 2000-09-06
NZ502249A (en) 2001-11-30
CA2296466A1 (en) 1999-02-11
CO4970688A1 (es) 2000-11-07
ID24374A (id) 2000-07-13
ATE259827T1 (de) 2004-03-15
EP1000086A1 (en) 2000-05-17
ZA986874B (en) 2000-01-31
JP3463928B2 (ja) 2003-11-05
HUP0004793A3 (en) 2001-10-29
EA200000086A1 (ru) 2000-08-28
HRP980417B1 (en) 2002-10-31
SK1012000A3 (en) 2000-09-12
US6194429B1 (en) 2001-02-27
UY25113A1 (es) 2000-12-29
OA11281A (en) 2002-11-19
TNSN98146A1 (fr) 2005-03-15
IS5339A (is) 2000-01-14
DK1000086T3 (da) 2004-05-17
PL338477A1 (en) 2000-11-06
TW538043B (en) 2003-06-21
EP1000086B1 (en) 2004-02-18
PA8456701A1 (es) 2000-05-24
HRP980417A2 (en) 1999-08-31
MA24626A1 (fr) 1999-04-01
AR015417A1 (es) 2001-05-02
HUP0004793A2 (hu) 2001-04-28
DZ2576A1 (fr) 2003-02-22

Similar Documents

Publication Publication Date Title
PE103799A1 (es) Procedimiento de purificacion de mesilato de alatrofloxacino
BRPI9917718B8 (pt) bactéria pertencente ao gênero escherichia e tendo uma capacidade para produzir um l-aminoácido selecionado do grupo que consiste de ácido l-glutâmico, l-histidina, l-prolina e l-treonina, e, processo para produzir um l-aminoácido selecionado do grupo que consiste de ácido l-glutâmico, l-histidina, l-prolina e l-treonina.
AU7415501A (en) Method for purifying a composition containing at least an internal dehydration product for a hydrogenated sugar
BR0200782A (pt) Compostos para o tratamento da isquemia
BR9909358A (pt) Composto, composição farmacêutica, e, processo para prevenção ou alìvio de complicações crÈnicas decorrentes de diabetes melito
BR0111206A (pt) Derivados de arilmetilamina para uso como inibidores de triptase
BR9610838A (pt) Processo para tratar um indivìduo tendo uma condição patológica envolvendo neovascularização.
MY137508A (en) Chemical compounds
BR0209127A (pt) compostos, composições farmacêuticas, métodos para o tratamento de dores, métodos para a modulação de uma resposta farmacológica e usos de compostos
BR0307833A (pt) Sìntese controlada de ziprasidona e suas composições
BR0114321A (pt) Composto, composição farmacêutica, uso de um composto, método de tratamento ou profilaxia de doenças inflamatórias, e, processo para preparar um composto
IL172773A0 (en) Formulations for the treatment of arhritis conditions
CY1108808T1 (el) Ενωσεις μοτιλιδης
BR9708114A (pt) Análogos xantona para o tratamento de doenças infecciosas.
IL172868A0 (en) Process for preparing an alpha-1-antitrypsin solution
EA200700044A1 (ru) Композиция для местного применения
ATE334690T1 (de) Zusammensetzungen zur behandlung von bindegeweben,die ein eisen(ii)-ion und ascorbat enthalten
EA200300450A1 (ru) Фармацевтические растворы соединений модафинила
BR9712141A (pt) Aplicação de 1-hifróxi-2-piridonas para tratamento de infecções cutâneas.
GT199900081A (es) Compuestos de sulfonilbenceno como agentes anti-inflamatorios / analgesicos.
CA2266759A1 (en) 3-mercaptoacetylamino-1,5-substituted-2-oxo-azepan derivatives useful as inhibitors of matrix metalloproteinase
BR0311385B1 (pt) oxatinacarboxamidas, seu processo de preparação e seu emprego, agente e seu processo de preparação, bem como processo para o combate de microorganismos indesejados
ES2108977T3 (es) Derivados del acido hidroximetilfurazanocarboxilico y su utilizacion en el tratamiento de enfermedades cardiovasculares.
EA200001029A1 (ru) Производные гигромицина
ATE279918T1 (de) Verwendung von aloe-emodin zur behandlung von neuroektodermalen tumoren

Legal Events

Date Code Title Description
FG Grant, registration
FD Application declared void or lapsed